

# NEWS RELEASES

CSE:BLR | Frankfurt: OJJ | US-OTC:BLRZF

[2022 \(/news/2022.html\)](/news/2022.html)

[2021 \(/news/2021.html\)](/news/2021.html)

[2020 \(/news/2020-1.html\)](/news/2020-1.html)

## Blackhawk's MindBio Therapeutics Invests NZ\$2.3 Million to Fast Track Psychedelic Microdosing Phase 2 Clinical Trials



[\(http://www.blackhawkcorp.ca/\)](http://www.blackhawkcorp.ca/)

Vancouver, British Columbia - TheNewswire - March 10, 2022 - Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:OJJ) (the "**Company**" or "**Blackhawk**") is pleased to announce that its 100% owned subsidiary, MindBio Therapeutics Pty Ltd. ("MindBio"), has invested NZ\$2,300,000 at a world class Australasian University to advance its psychedelics microdosing clinical trials.

MindBio is investing in world-class facilities to fast track its microdosing clinical trials. MindBio's Phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide) to 80 patients at home is due for completion shortly. Two continuation studies will follow from the NZ\$2,300,000 investment including a Phase 2 clinical trial microdosing LSD in patients with major depressive disorder and a Phase 2 clinical trial microdosing LSD in late-stage cancer patients starting this year.

These clinical trials have also received government grants amounting to NZ\$800,000 in funding to date to support this important clinical research into these emerging treatments.

This funding helps to accelerate intellectual property development in psychedelic microdosing, associated technology and important clinical trial work for determining safety and efficacy across different patient groups.

"MindBio is leading the charge on clinical trials of microdosing psychedelics," says Frederick Pels, CEO of Blackhawk Growth. "With our Phase 1 clinical trial near completion in addition to substantial progress on our two Phase 2 clinical trials, it puts MindBio ahead of many of its peers in the development of intellectual property that one day may lead to helping patients with mental health conditions."

### About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel <https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A> (<https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A>).

Please join the conversation on our Blackhawk group supporter's telegram group at <https://t.me/Blackhawkgrowthcorp> (<https://t.me/Blackhawkgrowthcorp>) and visit us online at <https://www.blackhawkgrowth.com>.

For further information please contact:

**Frederick Pels, Chief Executive Officer**

**(403)-991-7737**

**[fred@blackhawkgrowth.com](mailto:fred@blackhawkgrowth.com)**

***Cautionary Note Regarding Forward-Looking Statement***

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company cautions that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire - All rights reserved.



10

[HOME \[ / \]](#)   [ABOUT US \[ /ABOUT-US.HTML \]](#)   [INVESTORS \[ /INVESTORS/STOCK-INFO.HTML \]](#)   [INVESTMENTS \[ /INVESTMENTS/MEDIGEN-TBG.HTML \]](#)   [NEWS \[ /NEWS/2022.HTML \]](#)  
[CONTACT \[ /CONTACT.HTML \]](#)

© Copyright - 2022 Blackhawk Growth Corp. | [Website by Sandman Media Inc. \(http://www.sandmanmedia.com\)](http://www.sandmanmedia.com)